JUN 24, 2019 09:43 AM PDT

'Sugar-coating' proteins to treat pancreatitis?

WRITTEN BY: Nouran Amin

A powerful biomarker created by complex sugar molecules, called CA19-9, may be a target for the treatment of pancreatitis. Pancreatitis is an inflammatory disease of the pancreas that results in 275,000 annual hospitalizations in the United States. Individuals with hereditary pancreatitis are at risk in developing pancreatic cancer.

Learn more about pancreatitis:

"Pancreatitis is required for developing pancreatic cancer, and we might be able to prevent that transition in patients with pancreatitis by targeting CA19-9," says Dannielle Engle, a former Cold Spring Harbor Laboratory (CSHL) Cancer Center postdoctoral fellow and appointed Assistant Professor at Salk Institute "By targeting CA19-9 with antibodies in animal models, we were able to reduce the severity of pancreatitis and even prevent it from occurring."

Credit, Cold Spring Harbor Laboratory (CSHL): Pancreatic lineage immunofluorescence (IF) of the whole body, R;F CA19-9 mouse model.

Findings were published in the journal Science and describes that mice who produced CA19-9--a complex sugar structure that coats many proteins but had not been previously ascribed with any particular function--surprisingly developed severe pancreatitis. CA19-9 was also shown to dramatically result in the the growth of pancreatic tumors. Overall, the findings conclude that CA19-9 may be an attractive therapeutic target for pancreatitis.

"This is one of those unique opportunities where prophylactic intervention of pancreatitis may lead to prevention of pancreatic cancer in at-risk patients," Engle said.

An application was filed by CSHL in current pending status for the use of CA19-9 antibodies for treating and preventing pancreatitis.

Source: Cold Spring Harbor Laboratory (CSHL)

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 18, 2019
Drug Discovery
JUL 18, 2019
Investigational Drug Reverses High Cholesterol and Non-Alcoholic Fatty Liver Disease
A novel molecular pathway was recently discovered for an enzyme inhibitor in humans that is implicated in the development of high cholesterol and nonalcoho...
JUL 18, 2019
Drug Discovery
JUL 18, 2019
Discovery of Biomarker Target for Melanoma
According to a study published in the journal Cancer Research, researchers have discovered a biomarker that could serve as a possible therapeutic target fo...
JUL 18, 2019
Drug Discovery
JUL 18, 2019
New Viable Drug Target for Prostate Cancer
In the research community, MYC is historically known to be a difficult oncogene to target in cancer therapy. However, a recent study in the Journal of Cell...
JUL 18, 2019
Health & Medicine
JUL 18, 2019
FDA Approves Vyleesi - "The Female Viagra" for Premenopausal Women
Last Friday, the FDA approved a new drug that some are referring to as “the female Viagra.” Vyleesi, the drug’s market name, is injectabl...
JUL 18, 2019
Drug Discovery
JUL 18, 2019
Anticholinergic Drugs and Dementia?
A link between anticholinergic drug use and cognitive impairment was recently observed from observational studies on randomized clinical trials. Regenstrie...
JUL 18, 2019
Drug Discovery
JUL 18, 2019
The Composition of Cerebrospinal Fluid in MS patients Could Be The Key To Treatments That Halt Progression
The range of disability for individuals living with multiple sclerosis (MS) varies significantly depending on the relapsing/remitting form of the disease....
Loading Comments...